RECRUITING

Developing an Opioid Taper Intervention Before Total Joint Arthroplasty

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.

Official Title

Developing and Testing an Opioid Taper Intervention Before Total Knee Arthroplasty: Phase 2 Intervention Development

Quick Facts

Study Start:2024-01-10
Study Completion:2025-03-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05788016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks
  2. * currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months
  3. * have a reliable telephone number for contact
  4. * speaks English
  1. * Taking opioid medications that include:
  2. * Buprenorphine
  3. * Methadone
  4. * Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine)
  5. * Transdermal formations of opioid pain medications (e.g., fentanyl patches)

Contacts and Locations

Study Contact

Kevin R Riggs, MD
CONTACT
205-934-0778
kriggs@uabmc.edu
Shakristal Williams
CONTACT
205-934-2304
shakristalwilliams@uabmc.edu

Principal Investigator

Kevin R Riggs, MD
PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham

Study Locations (Sites)

UAB Hospital-Highlands
Birmingham, Alabama, 35205
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

  • Kevin R Riggs, MD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-10
Study Completion Date2025-03-03

Study Record Updates

Study Start Date2024-01-10
Study Completion Date2025-03-03

Terms related to this study

Keywords Provided by Researchers

  • Opioids

Additional Relevant MeSH Terms

  • Arthritis Knee
  • Arthritis Hip
  • Chronic Pain